Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 16, 2024 - Issue
Submit an article Journal homepage
105
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Sergio Di Matteo1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, ItalyView further author information
,
Roberto Freilone2 Dipartimento di Oncologia - Direttore SC Ematologia, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino e componente Tumor Molecular Board (TMB) Regione Piemonte, Torino, ItalyView further author information
,
Giacomo Matteo Bruno1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy;3 Department of Drug Sciences, University of Pavia, Pavia, ItalyORCID Iconhttps://orcid.org/0000-0003-4571-654XView further author information
ORCID Icon,
Rosario Notaro4 Direttore S.C. Core Research Laboratory in ISPRO, Firenze, ItalyView further author information
,
Sabrin Moumene1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, ItalyView further author information
,
Nicoletta Martone5 Sobi S.r.l., Milano, ItalyView further author information
,
Cristina Teruzzi5 Sobi S.r.l., Milano, ItalyView further author information
,
Antonio Ciccarone1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, ItalyView further author information
&
Giorgio Lorenzo Colombo1 Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy;3 Department of Drug Sciences, University of Pavia, Pavia, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5790-8891View further author information
ORCID Icon show all
Pages 225-232 | Received 31 Oct 2023, Accepted 26 Mar 2024, Published online: 10 Apr 2024

Figures & data

Figure 1 Cost effectiveness acceptability curve (CEAC) – Pegcetacoplan vs Ravulizumab.

Figure 1 Cost effectiveness acceptability curve (CEAC) – Pegcetacoplan vs Ravulizumab.

Figure 2 Cost effectiveness acceptability curve (CEAC) – Pegcetacoplan vs Eculizumab.

Figure 2 Cost effectiveness acceptability curve (CEAC) – Pegcetacoplan vs Eculizumab.

Table 1 Final Results – Summary

Table 2 Final Results – Details

Table 3 Utility – Details

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.